$ELDN
Eledon Pharmaceuticals, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024060025 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.396M $3.459M
YoY Change 39.42% 15.42%
% of Gross Profit
Research & Development $10.11M $7.410M
YoY Change 40.34% -8.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $14.50M $10.87M
YoY Change 40.06% -2.17%
Operating Profit -$14.50M -$10.87M
YoY Change 40.06% -2.17%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $869.0K $574.0K
YoY Change 12.13% 69.82%
Pretax Income -$44.91M -$10.30M
YoY Change 368.81% -4.43%
Income Tax
% Of Pretax Income
Net Earnings -$44.91M -$10.30M
YoY Change 368.81% -4.43%
Net Earnings / Revenue
Basic Earnings Per Share -$1.06 -$0.34
Diluted Earnings Per Share -$1.06 -$0.34
COMMON SHARES
Basic Shares Outstanding 38.51M 24.81M
Diluted Shares Outstanding 42.28M 29.99M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $83.61M $42.86M
YoY Change 17.14% -7.79%
Cash & Equivalents $26.04M $5.655M
Short-Term Investments $57.57M $37.21M
Other Short-Term Assets $157.0K $54.00K
YoY Change -34.03% 14.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $87.22M $47.98M
YoY Change 18.47% -1.9%
LONG-TERM ASSETS
Property, Plant & Equipment $621.0K $270.0K
YoY Change 12.3% -58.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $255.0K $185.0K
YoY Change 13.84% -49.86%
Total Long-Term Assets $33.26M $32.84M
YoY Change 0.3% -1.68%
TOTAL ASSETS
Total Short-Term Assets $87.22M $47.98M
Total Long-Term Assets $33.26M $32.84M
Total Assets $120.5M $80.82M
YoY Change 12.83% -1.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.148M $1.864M
YoY Change -2.23% -34.64%
Accrued Expenses $3.877M $2.383M
YoY Change 43.43% -9.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.025M $4.247M
YoY Change 22.96% -22.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $121.2M $0.00
YoY Change 65773.37% -100.0%
Total Long-Term Liabilities $121.2M $0.00
YoY Change 65773.37% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.025M $4.247M
Total Long-Term Liabilities $121.2M $0.00
Total Liabilities $129.0M $5.999M
YoY Change 1786.83% -20.16%
SHAREHOLDERS EQUITY
Retained Earnings -$387.9M -$253.5M
YoY Change 73.79% 18.68%
Common Stock $379.4M $328.3M
YoY Change 17.41% 13.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.501M $74.82M
YoY Change
Total Liabilities & Shareholders Equity $120.5M $80.82M
YoY Change 12.83% -1.81%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$44.91M -$10.30M
YoY Change 368.81% -4.43%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.774M -$8.741M
YoY Change -5.44% -11.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$19.91M $9.783M
YoY Change -34.35%
Cash From Investing Activities -$19.91M $9.783M
YoY Change -34.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.07M 1.000K
YoY Change 45.59%
NET CHANGE
Cash From Operating Activities -7.774M -8.741M
Cash From Investing Activities -19.91M 9.783M
Cash From Financing Activities 48.07M 1.000K
Net Change In Cash 20.38M 1.043M
YoY Change -468.08% -110.51%
FREE CASH FLOW
Cash From Operating Activities -$7.774M -$8.741M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001404281
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-36620
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ELEDON PHARMACEUTICALS, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1000967
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
19800 MacArthur Blvd
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2024Q1 dei City Area Code
CityAreaCode
(949)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
238-8090
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
ELDN
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38506614
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5655000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4612000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
37207000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
46490000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5115000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
47977000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
56129000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
270000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
365000
CY2024Q1 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2023Q4 eldn In Process Research And Development
InProcessResearchAndDevelopment
32386000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
185000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
186000
CY2024Q1 us-gaap Assets
Assets
80818000
CY2023Q4 us-gaap Assets
Assets
89066000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1864000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
967000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
284000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2099000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4247000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3895000
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1752000
CY2024Q1 us-gaap Liabilities
Liabilities
5999000
CY2023Q4 us-gaap Liabilities
Liabilities
5647000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24813130
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24813130
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24213130
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24213130
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
328280000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
326586000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253486000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-243191000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
74819000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83419000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80818000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89066000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7410000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8113000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3459000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2997000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
10869000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
11110000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10869000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11110000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
574000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
338000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10295000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29989400
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29989400
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285905
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
83419000
CY2024Q1 eldn Issuance Of Common Stock In Connection With Exercise Of Pre Funded Warrants Value
IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue
1000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1694000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
74819000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
84183000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
74792000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10295000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2024Q1 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
95000
CY2023Q1 eldn Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
92000
CY2024Q1 eldn Accretion On Investment Discounts
AccretionOnInvestmentDiscounts
-500000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1694000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1381000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
87000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-471000
CY2024Q1 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
451000
CY2023Q1 eldn Accounts Payable Accrued Expenses And Other Liabilities
AccountsPayableAccruedExpensesAndOtherLiabilities
-1018000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-99000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-78000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8741000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9924000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
12917000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22700000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9783000
CY2024Q1 eldn Proceeds From Issuance Of Common Stock And Pre Funded Warrants Net
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet
1000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1043000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9924000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4612000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56409000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5655000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46485000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10300000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-253500000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
42900000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.</span></p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.</span></p>
CY2024Q1 eldn Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
three months or less
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37207000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37207000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
46490000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
46490000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
441000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
624000
CY2024Q1 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4211000
CY2023Q4 eldn Prepaid Clinical Expense
PrepaidClinicalExpense
4128000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
409000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
185000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
54000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
90000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5115000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5027000
CY2024Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
969000
CY2023Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2003000
CY2024Q1 eldn Accrued Clinical Current
AccruedClinicalCurrent
948000
CY2023Q4 eldn Accrued Clinical Current
AccruedClinicalCurrent
451000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
132000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
47000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
50000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
44000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2099000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2545000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2024Q1 eldn Lessee Operating Lease Remaining Term Of Contract
LesseeOperatingLeaseRemainingTermOfContract
P9M
CY2024Q1 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
102000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
83000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y8M12D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0247
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0249
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
287000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
287000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
284000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
284000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2024Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2024Q1 eldn Contingent Liability
ContingentLiability
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20964302
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1694000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1381000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10295000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-10772000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29989400
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29989400
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14285905
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14285905
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34174075
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10238199
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-060025-index-headers.html Edgar Link pending
0000950170-24-060025-index.html Edgar Link pending
0000950170-24-060025.txt Edgar Link pending
0000950170-24-060025-xbrl.zip Edgar Link pending
eldn-20240331.htm Edgar Link pending
eldn-20240331.xsd Edgar Link pending
eldn-ex31_1.htm Edgar Link pending
eldn-ex31_2.htm Edgar Link pending
eldn-ex32_1.htm Edgar Link pending
eldn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
eldn-20240331_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending